Sera from patients with systemic lupus erythematosus demonstrate enhanced IgG binding to endothelial cells pretreated with tumour necrosis factor alpha.
Fluorescence flow cytometry and indirect immunofluorescence were used to detect circulating IgG antiendothelial cell antibodies (IgG-AECA) in the sera of patients suffering from rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and progressive systemic sclerosis (PSS). Pretreatment of endothelial cells with tumour necrosis factor alpha (TNF alpha), but not with interferon gamma (IFN gamma), increased the IgG binding from sera of some patients with active SLE. In contrast, no change in binding activity to cytokine-stimulated endothelial cells was observed in the RA and PSS sera. The results of this study suggested that the enhanced binding of IgG from the sera of patients with SLE to endothelial cells stimulated with TNF alpha may be due to the ability of this cytokine to increase the expression of potential antigens on the surface of these cells. Hence, TNF alpha may play a role in the immune-mediated vascular damage associated with SLE.
Quadros
N P
NP
Department of Immunology, Flinders Medical Centre, South Australia, Australia.
Roberts-Thomson
P J
PJ
Gallus
A S
AS
D001172:Arthritis, Rheumatoid / Q000097:blood; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D005434:Flow Cytometry; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007074:Immunoglobulin G / Q000187:drug effects / Q000378:metabolism*; D007371:Interferon-gamma / Q000187:drug effects / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D012044:Regression Analysis; D012595:Scleroderma, Systemic / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D007074:Immunoglobulin G; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma